6ZGV
Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
Summary for 6ZGV
Entry DOI | 10.2210/pdb6zgv/pdb |
Descriptor | Galactokinase, beta-D-galactopyranose, 2-(1,3-benzoxazol-2-ylamino)spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclohexane]-5-one, ... (5 entities in total) |
Functional Keywords | galk1, galactokinase 1, fragment screening, allosteric fragment, binding hotspt, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 4 |
Total formula weight | 174251.30 |
Authors | Mackinnon, S.R.,Bezerra, G.A.,Zhang, M.,Foster, W.,Krojer, T.,Brandao-Neto, J.,Douangamath, A.,Arrowsmith, C.,Edwards, A.,Bountra, C.,Brennan, P.,Lai, K.,Yue, W.W. (deposition date: 2020-06-20, release date: 2020-07-29, Last modification date: 2024-01-24) |
Primary citation | Mackinnon, S.R.,Krojer, T.,Foster, W.R.,Diaz-Saez, L.,Tang, M.,Huber, K.V.M.,von Delft, F.,Lai, K.,Brennan, P.E.,Arruda Bezerra, G.,Yue, W.W. Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia. Acs Chem.Biol., 16:586-595, 2021 Cited by PubMed: 33724769DOI: 10.1021/acschembio.0c00498 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report